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Abstract
A better understanding of the molecular mechanisms governing stem cell self-renewal
will foster the use of different types of stem cells in disease modeling and cell therapy strate-
gies. Immortalization, understood as the capacity for indefinite expansion, is needed for the
generation of any cell line. In the case of v-myc immortalized multipotent human Neural
Stem Cells (hNSCs), we hypothesized that v-myc immortalization could induce a more de-
differentiated state in v-myc hNSC lines. To test this, we investigated the expression of sur-
face, biochemical and genetic markers of stemness and pluripotency in v-myc immortalized
and control hNSCs (primary precursors, that is, neurospheres) and compared these two
cell types to human Embryonic Stem Cells (hESCs) and fibroblasts. Using a Hierarchical
Clustering method and a Principal Component Analysis (PCA), the v-myc hNSCs associat-
ed with their counterparts hNSCs (in the absence of v-myc) and displayed a differential ex-
pression pattern when compared to hESCs. Moreover, the expression analysis of
pluripotency markers suggested no evidence supporting a reprogramming-like process de-
spite the increment in telomerase expression. In conclusion, v-myc expression in hNSC
lines ensures self-renewal through the activation of some genes involved in the mainte-
nance of stem cell properties in multipotent cells but does not alter the expression of key
pluripotency-associated genes.
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Introduction
Tissue specific multipotent stem cells, patient-derived induced Pluripotent Stem Cells (iPSCs)
and autologous Adult Stem Cells (ASC) have enormous clinical potential for the research and
treatment of degenerative diseases and genetic disorders. Proliferation of primary cells and safety
concerns remain substantial roadblocks to overcome, exemplified by the heterogeneity of the cell
populations, the potential for genetic and epigenetic abnormalities, the tumorigenicity, and the
immunogenicity of transplanted cells [1]. Thus, understanding the mechanisms controlling stem
cell self-renewal is critical for boosting the efficiency and safety of stem cells in clinical research.
Complete reprogramming to pluripotency comprises intermediate stages between the initia-
tion of reprogramming and the stabilization of pluripotency. The cells in these intermediate
stages could be useful for many therapeutic indications, particularly in terms of safety [2,3]. In
this context of intermediate precursors, it was long ago hypothesized that v-myc immortalized
human Neural Stem Cells (hNSCs) could represent more de-differentiated cells [4,5].
V-myc is the viral homolog of c-Myc, initially identified in an acute avian retrovirus
(MC29), that belongs to a family of transcription factors that are able to bind to approximately
10–15% of the genome [6], controlling many cellular processes: it stimulates cell proliferation
and stemness, represses differentiation and ergo, connects cell cycle regulation to the mainte-
nance of pluripotency.
In addition, it is well established that v-myc promotes an unlimited proliferation and stabili-
ty of neural progenitor’s properties in the absence of long-term transformation [7,8]. Further-
more, the regulatable expression of v-mycmaintains a safe, effective and efficient self-renewing
state [9]. Taking these results into account we hypothesized if the stable expression of v-myc
could theoretically originate an intermediate population of more de-differentiated progenitors.
Deciphering the role of MYC is therefore important for understanding the maintenance of
stemness and pluripotency. To date, c-Myc has been shown to boost the initial reprogramming
by upregulating its targets during the first wave of the reprogramming process [10]. However,
it fails to completely reprogram to pluripotency on its own [11–16]. Several hypothesis propose
different roles of the Myc family of transcription factors in partial reprogramming and in the
enhancement of cell renewal [17]: 1) Myc could be implicated in the selection of a rare popula-
tion of cells with predetermined traits to undergo pluripotency [18]; 2) Myc could probably
modify epigenetic patterns inducing changes in chromatin [19,20] 3) Myc could promote the
de-differentiation or blockade of additional differentiation [21]; 4) Myc could induce a cell
cycle program specifically needed for self-renewal, by accelerating cell cycle progression (acti-
vating cyclins and inhibiting cyclin-dependent kinases (Cdk) activity [22] and increasing telo-
merase activity [8,15]). Moreover, Myc’s ability to immortalize cell cultures probably helps the
progression of reprogramming, as it has been shown that immortalization and indefinite prop-
agation is one of the essential features of reprogrammed-like cells [23].
In summary, as it has been previously proposed, v-mycmediated immortalization could not
only promote cell division, but could also return hNSCs to an earlier developmental state. One
therefore may hypothesize that v-myc immortalized hNSCs could acquire traits of pluripotency. In
this study, we investigated whether a single transgene, v-myc, ectopically expressed in hNSCs may,
in addition to sustaining cellular self-renewal, induce an intermediate, more de-differentiated state.
Materials and Methods
1. Cell Culture
1.1. Bioethics. All the cells originated from tissues donated for research after written in-
formed consent, and following European Union (EU) directives, the declaration of Helsinki,
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ethical guidelines of the European Network for Transplantation (NECTAR) and Spanish Bio-
medical Research Law, July 2007. All procedures were also approved by the Bioethics of Re-
search Committee of the University Autónoma de Madrid (Spain), the Ethics Committee for
Clinical Research of the local Government of Madrid (CEIC-Regional), and the national au-
thority (Instituto de Salud Carlos III (Spain)).
1.2. Cell lines of hNSCs. We have used the hNS1, hCTX, hVM1 cell lines. Cell isolation
and immortalization have been previously described [7, 8, 37–40]. For experiments, cells were
seeded at 10,000 cell/cm2(unless otherwise indicated) on poly-L-lysine (10μg/ml; Sigma-Al-
drich) coated plastic or poly-L-lysine (25–50 μg/ml) glass coverslips with HSC medium, a
chemically defined medium [Dulbecco’s Modified Eagle Medium (DMEM):F12 (1:1) with Glu-
taMAX-I medium (Gibco) containing 1% AlbuMAX (Gibco), 50 mMHepes (Gibco), 0.6% D-
Glucose, 1% N2 supplement (Gibco), 1% non essential amino acids mixture (NNEA), and 1%
penicillin-streptomycin (P/E)]. The HSC medium was supplemented with Epidermal Growth
Factor (EGF) and basic Fibroblast Growth Factor (bFGF) (20 ng/ml, R&D system) to promote
cell proliferation. Cells were maintained at standard normoxic culture conditions proliferated
at 37°C, and 95% humidity in a 5% CO2 and normal atmospheric oxygen levels (20% O2) ex-
cept for hVM1 cells that were incubated in a 5% O2–5% CO2 levels (dual CO2/N2 incubator,
Forma). Samples for analyses were collected at least 48h following the last passage
by trypsinization.
1.3. Non-immortalized forebrain human Neural Progenitor Cells (hNPCs). Neuro-
spheres were obtained from forebrain tissue derived from aborted human fetuses of 9.5 and
10 weeks gestational age (Lund University Hospital/ Wallenberg Neuroscience Center; Dr.
Bengt Juliusson; Lund, Sweden). Neurospheres were grown in suspension in HSC medium
supplemented with EGF and bFGF (20 ng/ml, R&D system) and heparin (5 μg/ml) and
passed twice by mechanical protocols. Cells were maintained in standard normoxic culture
conditions. When used for experimentation, they were seeded as adherent cultures
(10,000 cells/cm2) on poly-L-lysine (10μg/ml; Sigma-Aldrich) coated plastic or poly-L-lysine
(25–50 μg/ml) glass coverslips also treated with laminin (2,5 μg/ml) in proliferation
conditions.
1.4. Human foreskin Fibroblast cell lines. The commercial hFF-1 line was used (Ameri-
can Type Culture Collection, LGC Standards, SCRC-1041TM). Cells were proliferated in stan-
dard normoxic culture conditions. Cells were seeded at 10,000 cells/cm2 on coated plastic
previously treated with 0,1% Gelatin (Merck) in Phosphate Buffered Saline (PBS) or glass cov-
erslips treated with 0.2% Gelatin in PBS. The culture medium consisted in DMEM (Gibco),
10% FBS and 1% L-Glutamine. When used as feeders, mitomycin C was added (7μg/ml or
1μg/ml, 3 hours or overnight, respectively) when the cells were confluent. After that, medium
was changed every three days until used as feeders.
1.5. Embryonic stem cell lines. In the present study we have used representative hESC
lines such as HS181 [41] and H9 [42]. The cells were seeded in a confluent conditioned fibroblast
medium, and maintained in standard normoxic culture conditions. The cells grew as colonies in
a hESC medium [80% Knockout DMEM (Gibco), 20% Serum Replacement (Gibco), 200 mM
L-Glutamine, 1% NNEA, 1% P/E, 0,1 mM of β-Mercapto Ethanol, and bFGF (final concentra-
tion of 4ng/ml, R&D system)]. Human ESCs were split upon treatment with Accutase (PAA
LabClinics), scratched and gently aspirated with a p10 pipette avoiding removing the hFF-1 feed-
er layer. Next, they were centrifuged during 5 min at 55g and seeded at 10,000 cells/cm2 onto a
fresh hFF-1 feeder layer.
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2. RNA Isolation and Real Time-Quantitative-Polymerase Chain
Reaction (RT-Q-PCR)
Total RNA was extracted using the High Pure RNA isolation Kit (Roche) following manufac-
turer’s guidelines. Total RNA was then quantified by absorption at 260 nm in a Nanodrop
spectrophotometer. Samples with 260/280 and 260/230 ratios in the range of 1.8–2 and 2–2.35,
respectively, were accepted. Microfluidic RT-Q-PCR was performed in triplicate using the Taq-
Man Human Stem Cell Pluripotency Array (Applied Biosystems). Regular RT-Q-PCR was per-
formed as previously described [43] using the ABI PRISM 7900 HT Sequence Detection
System. One μg of RNA for each sample was subjected to reverse transcription using the High
Capacity cDNA Achieve Kit (Applied Biosystems). For Real Time-Q-PCR 0.5 μg cDNA was
amplified using TaqMan based technology (Applied Biosystems). The expression data were
normalized taking into account the values of the genes that were expressed in all samples. The
normalization formula is as follows: ΔCt(test) = (Ct(gene)-Ct(total average))/SD(Ct(total)).
3. Immunocytochemistry (ICC)
Two days following the last passage, the cultures were rinsed with 0.1 M PBS and fixed for
15 min in freshly prepared 4% Paraformaldehyde/Phenylalanine (PFA/PHE) /4% sucrose. Cul-
tures were blocked for 1h at room temperature in 10% normal horse serum or goat serum,
0.25% Triton X-100 in PBS (absent for surface proteins) and incubated overnight at 4°C with
primary antibodies (dissolved in 1% serum and 0.25% Triton X-100 in PBS) against SSEA-1
(1:100, mouse mAb, Hybridoma Bank MC480), SSEA-4 (1:100, mouse mAb, Millipore MAB
34304), Tra 1–60 (1:100, mouse mAb, Millipore MAB 4360), and Tra 1–81 (1:100, mouse mAb,
Millipore MAB4381, Nanog (1:100, goat pAb, R&D Systems AF1997), Oct3/4 (1:100, rabbit
pAb, Santa Cruz Biotechnology SC9081), Sox2 (1:100, rabbit mAb, Millipore AB5603), and Al-
kaline Phosphatase (AP) (1:50, mouse mAb, R&D Systems MAB1448). After removal of the pri-
mary antibodies, cultures were incubated with the secondary antibodies as FICT-conjugated
antibody (Alexa 488, 1:500, goat anti rabbit IgG, Molecular Probes A11034), Cy3-conjugated an-
tibodies (Texas Red, 1:500, goat anti mouse IgM, Vector Laboratories TI-2020; Alexa 594, 1:500,
chicken anti goat IgG, Molecular Probes a 21468; Cy3, 1:500, goat anti mouse IgG, Jackson
Inmuno Research Lab., Inc. 111-165-003). Appropriate controls included negative controls
where primary antibodies were omitted, and positive controls were hESCs, known to express the
antigens under study. Nuclei were counterstained with Hoechst 33258 (Molecular Probes) and
mounted with Mowiol (Polysciences 17958) and analyzed. Microscopic examination and pho-
tography of specimens were performed.
4. Alkaline Phosphatase Activity Analysis
The AP activity assay was performed according to the manufacturer’s instructions (Cell Bio-
labs, Inc., San Diego, CA). The activity was determined by measuring A405 and normalized
against the amount of protein in the assay. For quantification, three biological replicates were
used for each sample. The enzyme activity was expressed in international units (μmol of prod-
uct produced per minute and per μgram of protein; μmol x min−1 x μg−1).
5. Image Analysis
Analysis and photography of fluorescent cultures were done using a vertical fluorescence mi-
croscope Axioskop2 plus (Zeiss) coupled to a Coolsnap FX color camera navigated by Metavue
5.07 (Universal Imaging) operated by Adobe Photoshop 5.0 (Pantone Inc). Images have been
processed using the Adobe Design Premium CS5.
V-Myc and Re-Programming of hNSC
PLOSONE | DOI:10.1371/journal.pone.0118499 March 12, 2015 4 / 13
6. Statistical Analysis
General statistical analyses were run using Statistica vs7 (StatSoft.Inc. Tulsa OK). Results are
shown as the average ± Standard Error of the Mean (S.E.M.) of data, from four samples and
from four experiments, unless stated otherwise.
7. Bioinformatics Tools
The data discussed in this publication has been deposited in NCBI’s Gene Expression Omnibus
(GEO) and are accessible through GEO Series accession number GSE63710.
Clustering Analysis. Clustering of data was done with the program Gene Cluster vs.
3.0 using a Hierarchical clustering single linkage method. The distance measures were taken
based both on the Pearson correlation (centered) and Euclidean distance and both methods
gave the same results. Images of Tree Clustering were done by JavaTreeView vs. 1.1.6.
Principal Component Analysis. This analysis was done with 32 principal components,
with the R Program (R Project for Statistical Computing vs. 2.13.0). The first three components
were taken into account as are the ones that most contribute to the differences. Images of the
tridimensional graphic were prepared with Adobe PostScript CS5.
Results
To address the question of whether v-mycmodifies the stemness and potency of hNSCs, we
first studied the expression of 90 genes related to stemness, self-renewal and differentiation in
several v-myc immortalized cell lines (hNS1, hVM1, hCTX), non-immortalized neurospheres
(hNPCs derived from 9.5 and 10 weeks-old fetuses), hESCs (H9 and HS181) [24,25] and
human foreskin fibroblasts (hFF-1).
A hierarchical clustering was performed to group the cell lines under study in accordance
with their gene expression profiles (Fig. 1A). The analysis identified two main clusters which
segregate one from each other (that is, with the longest significant distance). Human ESCs
(hESCs) clustered together and segregated from the remaining cell lines, which comprised an-
other cluster. Within this second cluster, hFF-1 grouped independently from neural cells. Re-
garding neural cells, hNPCs and v-myc immortalized cortex cell line (hCTX) clustered
separately from v-myc immortalized ventral midbrain cell line (hVM1) and v-myc telencepha-
lon/diencephalon cell line (hNS1) (Fig. 1A). Thus, the hierarchical cluster analysis groups the
v-myc immortalized cells closer to hFF-1 than to hESCs. Attempts to separately cluster the
non-immortalized hNPCs and the v-myc immortalized hNSC cell lines using this analysis were
negative, indicating a high degree of similarity.
Then, the gene expression data were analyzed by Principal Component Analysis (PCA) to
verify gene expression differences and generate discrete groups among the studied cell lines, ac-
cording to the genes that contributed most to each separation (component). The three princi-
pal components explained 60% of the dataset variability. The first component contributes with
43% of the variability, and sorted the hESCs (H9 and HS181) out of the rest of the groups. The
second component contributes with 11% of the variability, which separated the fibroblasts
(hFF-1). Finally, the third component minimally separated the v-myc immortalized hNSCs
from their non-immortalized counterparts (neurospheres, hNPCs) with a variability of only
6% (Fig. 1B). Among the genes that substantially contributed to the differences between v-myc
immortalized hNSCs and neurospheres is the hTERT (Telomerase Reverse Transcriptase).
We next proceeded to perform a Principal Component Analysis of immortalized cells vs.
hNPCs. The three principal components contributed with 71% of the variability of the dataset.
The contribution of each component was 56%, 9% and 6% respectively (Fig. 1C). In order to
confirm both PCA results, a clustering analysis with the dataset of the components was
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performed for the PCA of the four cell lines (hESCs, hFF-1, hNPCs, and v-myc immortalized
cells) (Fig. 1B) and for the PCA of the v-myc immortalized cells and hNPCs (Fig. 1C). The clus-
tering of the PCA-dataset of the four cell lines confirmed the clustering previously done with
the normalized data, in which three groups cluster separately: hESCs, hNSCs and hFF-1
(Fig. 1B). However, the clustering of the PCA-dataset of the v-myc immortalized cells and
hNPCs did not separate these two cell types (Fig. 1C). Therefore, the PCA of the v-myc immor-
talized cells and hNPCs (non-immortalized neurospheres) demonstrate that there are not
Fig 1. Gene expression pattern of the different cell lines, clustering and PCA analysis. A) The array data were normalized and a hierarchical clustering
was run. On top of the heatmap, the dendrogram shows the clustering among the different samples. The classified list of the genes under study appears on
the right side of the heatmap. The Color Bar Expression Levels show the differences in gene expression: black means no differences, green means a high
expression, and red means low expression. Grey color mean No Expression (NE). B) Human Stem Cell Pluripotency Array (TaqMan) gene expression data
from the different studied cell lines were subjected to a PCA. The graph presents the first, second and third components. For every cell line, the dots
represent the value of each sample. To confirm the results of the PCA, a clustering analysis with the dataset of the components was done (right side of the
panel). C) PCA analysis of v-myc immortalized cells and non-immortalized hNPCs and the clustering of the PCA data to confirm the similarity between v-myc
immortalized and the hNPCs neurospheres according to the three components.
doi:10.1371/journal.pone.0118499.g001
V-Myc and Re-Programming of hNSC
PLOSONE | DOI:10.1371/journal.pone.0118499 March 12, 2015 6 / 13
significant gene expression markers capable of segregating the neural precursor/stem cell
group based on pluripotency and stemness.
In summary: firstly, the hierarchical clustering analysis unambiguously placed immortalized
v-myc cell lines and non-immortalized cell lines within the same group. Secondly, both cell
types were more related to a differentiated state, exemplified by hFF-1, than to an undifferenti-
ated state, represented by hESCs. Thirdly, the PCA analysis, comparing the four cell lines, only
found a variability between the v-myc immortalized cell lines and the non-immortalized coun-
terparts of 6%. According to these gene expression results, we suggest that the state of immor-
talized v-myc cell lines is undistinguishable from that of non-immortalized cell lines.
A second approach to assess our question of whether v-myc returns hNSCs to an early state
of de-differentiation was to study the standard pluripotency-related cell markers [26] by
immunocytochemistry in the v-myc immortalized lines in comparison to hESCs and hFF-1.
The markers studied included the surface hESC markers identified as the globoseries glyocoli-
pid antigens SSEA4 and SSEA1 (Stage-Specific Embryonic Antigens) and the keratin sulphate
antigens TRA1–61 and TRA 1–81. Considering the staining intensities of hESCs (positive con-
trol) and hFF-1 (negative control), the v-myc immortalized cells displayed only traces/residual
staining for TRA 1–60 and TRA 1–81 (Fig. 2). hNS1 cells showed some expression of SSEA4,
whereas only occasional cells were positive in hVM1 and hCTX. For the case of SSEA1, a mark-
er positive in committed cells, some signal is observed in hVM1 and hCTX, which are tissue
specific NSCs. Notably, the level of staining for these markers in the non-immortalized hNPCs
does not differ from that observed in the immortalized lines (Fig. 2). A second set of tested
markers included NANOG (Nanog homeobox), POU5F1 Octomer-4 (POU class 5 homeo-
box 1, formely known as OCT3/4,) SOX2 (member of the family of Sex determining region Y
Box 2), and AP (Alkaline Phosphatase). In relation to NANOG, OCT3/4, SOX2 and AP, vary-
ing degrees of staining were observed in the immortalized cells, making it difficult to draw any
firm conclusion. Whereas v-myc cells weakly stained for NANOG ICC, the cells did show a
positive stain for the other markers (Fig. 3). Similarly to the surface markers in Fig. 2, the level
of staining for NANOG, OCT3/4, SOX2 and AP in the non-immortalized hNPCs does not sub-
stantially vary from that observed in the immortalized lines.
In order to clarify the level of expression of NANOG, OCT3/4, SOX2, and that of the cata-
lytic subunit of telomerase, hTERT, their mRNA expression was quantified in v-myc immortal-
ized cells in comparison to hESCs. As shown in Fig. 4A and B, considering 100% of expression
in HS181 cells, v-myc immortalized cells express on average 39% of NANOG, and 68% of
OCT3/4. On the other hand, v-myc immortalized cells express on average 147% of SOX2 and
158% of hTERT (Fig. 4C and D).
Regarding AP, we performed an enzyme activity assay to correlate the positive histochemi-
cal staining pattern with the actual enzymatic activity. The measurement of this activity in
quantitative terms, (Fig. 4E) indicated that HS181 cells are endowed with a high AP specific ac-
tivity (0.26±0.52x10−3 μmol/min. μg, n = 3) compared with the very low activity of v-myc im-
mortalized cells (hNS1 = 0,01±2,82x10−3 μmol/min. μg, n = 3; hVM1 = 6,73x10−3±1.63x10−3
μmol/min. μg, n = 3; hCTX = 16.5x10−3±7.12x10−3 μmol/min. μg, n = 3) and fibroblasts
(17.7x10−3 ±15.1x10−3 μmol/min. μg, n = 3). Both experiments clarify that v-myc immortalized
cells express less NANOG and OCT3/4, and more SOX2 and hTERT when compared to
hESCs, and that AP activity is negligible in v-myc immortalized cells in comparison to hESCs.
In sum, these results confirm that v-myc does not induce the expression of pluripotency mark-
ers or traits in comparison to those of hESCs.
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Discussion
In the field of hNSCs research, the process of self-renewal is understudied, the question of the
molecular mechanisms by which v-myc immortalizes the cells still remains unanswered, and
the exact meaning of immortalization, apart from indefinite expansion, is poorly understood.
Our results help to clarify if v-myc exerts any effect on de-differentiating hNSCs from a multi-
potent state back to a more pluripotent state, similar to that of hESCs. Transcription factor-in-
duced reprogramming to pluripotency is a gradual and multistep process, with different stages
of reprogramming towards pluripotency. Early key events associated with reprogramming are
AP expression, followed by SSEA-1 silencing, and, later on, the activation of the endogenous
OCT3–4 and NANOG genes, key pluripotency regulators [2,3]. MYC has been shown to be
crucial for the loss of the somatic expression program, whereas OCT3–4, KLF-4 and SOX2
(OKS) induce the expression of pluripotency-associated genes [27]. The expression of telome-
rase (TERT) and the silencing of the X chromosome in female cells also correlate with the time
window when cells enter a self-sustaining pluripotent state. Aside from the differences in the
expression of pluripotency-related genes and activation of lineage-specific genes that are not
expressed in fully pluripotent stem cells [28], these intermediate cell populations usually show
differences in morphology. Neural stem cells endogenously express SOX2, c-MYC, KLF4, and
iPSCs have been derived from NSCs with OCT3–4 alone [29]. OCT3–4 seems to be the essen-
tial reprogramming factor for most initial cell types [30] but SOX2 synergistically activates the
Oct-Sox axis and enhances OCT3/4, regulating the expression of pluripotent stem-cell-specific
genes [31].
Fig 2. Immunocytochemistry of stemness surface markers. Staining was performed 48 hours following the last passage. From left to right: staining
displayed by hESCs (HS181 line, low and high magnification), hNPCs, v-myc immortalized lines (hNS1, hVM1, and hCTX) and fibroblasts (hFF-1). From top
to bottom the markers studied were: SSEA1, SSEA4, TRA1–60 and TRA1–81. Hoechst 33258 nuclear staining is shown in blue. Scale bar represents
100 μm for hESCs in the left hand column (low magnification) and 25 μm for all the other microphotographs.
doi:10.1371/journal.pone.0118499.g002
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Based on these studies, we hypothesized that v-myc immortalization could turn the cells
into a more undifferentiated state. However, our expression analysis demonstrates that the v-
myc-mediated immortalization rendered hNSCs to a very similar (non-pluripotent state) to
that shown by their multipotent counterparts in the absence of an exogenously expressedMyc.
Previously, we already described that hTERT, is quickly and directly upregulated by v-myc
in immortalized cells [8], and these results have been confirmed in the present study. Interest-
ingly, among several pluripotency-related genes, hTERT is the only one modulated by v-myc,
consistent with the results of the cluster analysis performed (Fig. 1). This result indicates that
v-myc hNSCs do not substantially differ from their non-immortalized counterparts, and at the
same time indicates that they are not similar to pluripotent cells. Furthermore, it seems that
hTERT activation may be a mechanism through which v-myc (and probably c-Myc) immortal-
ization acts [32]. This result is consistent with a recent study showing that high levels ofMyc
expression are important for sustaining the self-renewal properties of partial iPSCs and of
ESCs [33].
Lastly, the fact that v-myc immortalized hNSCs do not show traits of pluripotency actually
constitutes an advantage. It has been extensively demonstrated that v-myc immortalized cells
are not transformed, and therefore, concerns and debates about their safety remain speculative
[34–36]. Indeed, not sharing a molecular profile with pluripotent cells eliminates one further
concern, that of the possibility for tumor formation shown by hESCs and hiPSCs.
In conclusion, v-myc activates an immortalization program leading to the maintenance of
cell self-renewal and inhibition of cellular senescence yielding perpetual hNSC lines. This can
be easily explained by the activation of telomerase gene expression ([8] and present work).
However, v-myc induces these effects without inducing pluripotency-associated traits. It only
Fig 3. Immunocytochemistry of pluripotency markers. Staining was performed 48 hours following the last passage. From left to right: staining displayed
by hESCs (HS181 line, low and high magnifications), hNPCs, v-myc immortalized lines (hNS1, hVM1, and hCTX) and fibroblasts (hFF-1). From top to bottom
the markers studied were: NANOG, OCT3/4, SOX2 and AP. Hoechst 33258 nuclear staining is shown in blue. Scale bar represents 100 μm for hESCs in the
left hand column (low magnification) and 25 μm for all the other microphotographs.
doi:10.1371/journal.pone.0118499.g003
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Fig 4. Expression of pluripotency markers and quantification of alkaline phosphatase activity.mRNA levels were quantified by RT-Q-PCR. NANOG
(A), OCT3–4 (B), SOX2 (C) and hTERT (D) expression in the v-myc immortalized cell lines shows significant differences with the HS181 pluripotent cell line.
Data are the average ± S.E.M (n = 4). * P<0.05; one-way ANOVA, followed by a post-hoc LSD and Bonferroni test or non parametric Kruskal-Wallis and
median test followed by a post-hoc multiple comparisons of mean ranks for all groups. E) Quantification of alkaline phosphatase activity in the cell lines. Data
are the average ± S.E.M (n = 3). * P<0.05; non parametric Kruskal-Wallis and median test followed by a post-hoc multiple comparisons of mean ranks for all
groups.
doi:10.1371/journal.pone.0118499.g004
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activates the expression of one gene involved in sustaining stem cell properties in multipotent
cells (such as hTERT). Further studies are needed to clarify the molecular basis of immortaliza-
tion of hNSCs by v-myc, in order to understand how to indefinitely propagate hNSCs in its ab-
sence, replacing it with alternative factor(s).
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